{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:36:33Z","timestamp":1790753793230,"version":"4.1.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The ideal endpoint of antiviral therapy in chronic hepatitis B (CHB) patients is to clear hepatitis B surface antigen (HBsAg). This study aimed to evaluate whether the expression of functional molecules on plasmacytoid dendritic cells (pDCs) is associated with HBsAg loss in HBeAg-positive patients during peginterferon alpha-2a (PEG IFN \u03b1-2a) therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A single-center prospective cohort study was performed in HBeAg-positive CHB patients who were treated with PEG-IFN \u03b1-2a and followed up for 4 years. HBsAg clearance, HBeAg loss and undetectable HBV DNA achieved by PEG-IFN \u03b1-2a therapy was considered as functional cure. The frequencies of pDC and CD86<jats:sup>+<\/jats:sup> pDC in peripheral blood, and the mean fluorescence intensity of CD86 (CD86MFI) on the surface of pDC were measured at starting therapy, after 12 and 24 weeks of therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 63 patients enrolled, 17 patients achieved HBsAg loss. The baseline HBV DNA load in Non-functional-cure group was significantly higher than that in Functional cure group, and the CD86<jats:sup>+<\/jats:sup> pDC% was significantly lower in patients without functional cure. HBV DNA load (OR=0.146, <jats:italic>P<\/jats:italic> = 0.002) and CD86<jats:sup>+<\/jats:sup> pDC% (OR=1.183, <jats:italic>P<\/jats:italic> = 0.025) were independent factors associated with functional cure confirmed by binary logistic regression analysis. In the Functional cure group, HBsAg, HBeAg, and HBV DNA loads decreased remarkably after 12 weeks and 24 weeks of treatment compared to baseline. In Non-functional-cure group, CD86<jats:sup>+<\/jats:sup> pDC% and CD86MFI increased significantly from baseline after 12 weeks of treatment. In the Functional cure group, compared with baseline, pDC% increased significantly at 24 weeks, while CD86MFI increased significantly after 24 weeks of treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The lower the baseline HBV DNA load and the more the baseline CD86<jats:sup>+<\/jats:sup> pDC%, the easier it is for patients to obtain functional cure.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.891424","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T05:51:55Z","timestamp":1652939515000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Expression of Functional Molecule on Plasmacytoid Dendritic Cells Is Associated With HBsAg Loss in HBeAg-Positive Patients During PEG-IFN \u03b1-2a Treatment"],"prefix":"10.3389","volume":"13","author":[{"given":"Weihua","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyue","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjie","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuling","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,19]]},"reference":[{"key":"B1","unstructured":"GenevaWorld Health OrganizationGlobal Progress Report on HIV, Viral Hepatitis and Sexually Transmitted Infections, 2021: Accountability for the Global Health Sector Strategies 2016\u20132021: Actions for Impact2021"},{"key":"B2","unstructured":"Fact Sheet: Hepatitis B. 2019"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30119-0","article-title":"A Global Scientific Strategy to Cure Hepatitis B","volume":"4","author":"Revill","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.05.008","article-title":"Hepatitis B Cure: From Discovery to Regulatory Approval","volume":"67","author":"Lok","year":"2017","journal-title":"J Hepatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"311\u22125","DOI":"10.1007\/s12072\u2212007\u22129002\u22129","article-title":"Spontaneous Relapse of Hepatitis in Inactive HBsAg Carriers","volume":"1","author":"Chu","year":"2007","journal-title":"Hepatol Int"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2019.04.006","article-title":"Drugs in the Pipeline for HBV","volume":"23","author":"Lopatin","year":"2019","journal-title":"Clin Liver Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31408","article-title":"Have the Starting Lineup of Five for Hepatitis B Virus Covalently Closed Circular DNA Synthesis Been Identified","volume":"72","author":"Zhao","year":"2020","journal-title":"Hepatology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01032-19","article-title":"Revisiting Hepatitis B Virus: Challenges of Curative Therapies","volume":"93","author":"Hu","year":"2019","journal-title":"J Virol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1126\/science.1243462","article-title":"Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science"},{"key":"B11","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13148-020-00928-z","article-title":"IFN-\u03b1 Confers Epigenetic Regulation of HBV cccDNA Minichromosome by Modulating GCN5-Mediated Succinylation of Histone H3K79 to Clear HBV cccDNA","volume":"12","author":"Yuan","year":"2020","journal-title":"Clin Epigenet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.09.004","article-title":"Ultra Long-Term Follow-Up of Interferonalpha Treatment for HBeAg-Positive Chronic Hepatitis B Virus Infection","volume":"19","author":"Choi","year":"2021","journal-title":"Clin Gastroenter Hepat"},{"key":"B13","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/hep.28280","article-title":"Antiviral Therapy for Chronic Hepatitis B Viral Infection in Adults: A Systematic Review and Meta-Analysis","volume":"63","author":"Lok","year":"2016","journal-title":"Hepatology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14629","article-title":"Systematic Review With Meta-Analysis: Combination Treatment of Regimens Based on Pegylated Interferon for Chronic Hepatitis B Focusing on Hepatitis B Surface Antigen Clearance","volume":"47","author":"Qiu","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29213","article-title":"A Potent Hepatitis B Surface Antigen Response in Subjects With Inactive Hepatitis B Surface Antigen Carrier Treated With Pegylated-Interferon Alpha","volume":"66","author":"Cao","year":"2017","journal-title":"Hepatology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-031210-101345","article-title":"Plasmacytoid Dendritic Cells: Recent Progress and Open Questions","volume":"29","author":"Reizis","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e15324","DOI":"10.1371\/journal.pone.0015324","article-title":"Hepatitis B Virus Lacks Immune Activating Capacity, But Actively Inhibits Plasmacytoid Dendritic Cell Function","volume":"6","author":"Woltman","year":"2011","journal-title":"PLos One One"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31725","article-title":"Human Hepatitis B Virus Negatively Impacts the Protective Immune Crosstalk Between Natural Killer and Dendritic Cells","volume":"74","author":"De Pasquale","year":"2021","journal-title":"Hepatology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.759292","article-title":"Peripheral Immune Cells Exhaustion and Functional Impairment in Patients With Chronic Hepatitis B","volume":"8","author":"Jin","year":"2021","journal-title":"Front Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/jmv.24306","article-title":"The Role of DCs in the Immunopathogenesis of Chronic HBV Infection and the Methods of Inducing DCs Maturation","volume":"88","author":"Sun","year":"2016","journal-title":"J Med Virol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0026315","article-title":"Hepatitis B Virus Impairs TLR9 Expression and Function in Plasmacytoid Dendritic Cells","volume":"6","author":"Vincent","year":"2011","journal-title":"PLos One One"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1053\/j.gastro.2012.08.046","article-title":"Altered Functions of Plasmacytoid Dendritic Cells and Reduced Cytolytic Activity of Natural Killer Cells in Patients With Chronic HBV Infection","volume":"143","author":"Martinet","year":"2012","journal-title":"Gastroenterology"},{"key":"B23","article-title":"High-Dose Hepatitis B E Antigen Drives Mouse Bone Marrow-Derived Dendritic Cells to Differentiate Into Regulatory Dendritic Cells In Vitro","volume":"9","author":"Wu","year":"2016","journal-title":"Int J Clin Exper Pathol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2012.06.016","article-title":"Assessment of the Effect of Ribavirin on Myeloid and Plasmacytoid Dendritic Cells During Interferon-Based Therapy of Chronic Hepatitis B Patients","volume":"53","author":"Boltjes","year":"2013","journal-title":"Mol Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158297","article-title":"Pegylated Interferon \u03b1-2a Triggers NK-Cell Functionality and Specific T-Cell Responses in Patients With Chronic HBV Infection Without HBsAg Seroconversion","volume":"11","author":"Bruder Costa","year":"2016","journal-title":"PLos One One"},{"key":"B26","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1089\/jir.2018.0014","article-title":"Quantitation of Plasmacytoid Dendritic Cells in Chronic Hepatitis B Patients With HBeAg Positivity During PEG-IFN and Entecavir Therapy","volume":"38","author":"Cao","year":"2018","journal-title":"J Interferon Cytokine Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20366","article-title":"Functional Impairment of Myeloid and Plasmacytoid Dendritic Cells of Patients With Chronic Hepatitis B","volume":"40","author":"van der Molen","year":"2004","journal-title":"Hepatology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4103\/0366-6999.200554","article-title":"Kinetics of Hepatitis B Surface Antigen Level in Chronic Hepatitis B Patients Who Achieved Hepatitis B Surface Antigen Loss During Pegylated Interferon Alpha-2a Treatment","volume":"130","author":"Li","year":"2017","journal-title":"Chin Med J"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1323\u221231","DOI":"10.1111\/j.1365\u22122036.2010.04474.x","article-title":"Serum HBsAg Quantification to Predict Response to Peginterferon Therapy of E Antigen Positive Chronic Hepatitis B","volume":"32","author":"Chan","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1186\/1743\u2212422X\u221210\u221221","article-title":"Efficacy of Pegylated Interferon \u03b12a in Patients Without HBeAg Loss After the Withdrawal of Long\u2212Term Lamivudine Therapy","volume":"10","author":"Zhang","year":"2013","journal-title":"Virol J"},{"key":"B31","doi-asserted-by":"publisher","first-page":"88\u221297","DOI":"10.1007\/\/s12072\u2212012\u22129343\u2212x","article-title":"Hepatitis B Surface Antigen Levels: Association With 5\u2212Year Response to Peginterferon Alfa\u22122a in Hepatitis B E\u2212Antigen\u2212Negative Patients","volume":"7","author":"Marcellin","year":"2013","journal-title":"Hepatol Int"},{"key":"B32","doi-asserted-by":"publisher","first-page":"100\u22125","DOI":"10.1093\/cid\/cis859","article-title":"Close Monitoring of Hepatitis B Surface Antigen Levels Helps Classify Flares During Peginterferon Therapy and Predicts Treatment Response","volume":"56","author":"Sonneveld","year":"2013","journal-title":"Clin Infect Dis"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0122259","article-title":"Pegylated\u2212interferon Alpha Therapy for Treatment\u2212Experienced Chronic Hepatitis B Patients","volume":"10","author":"Yeh","year":"2015","journal-title":"PLos One One"},{"key":"B34","doi-asserted-by":"publisher","first-page":"929\u221235","DOI":"10.4103\/0366\u22126999.179802","article-title":"Dynamic Characteristics of Serum Hepatitis B Surface Antigen in Chinese Chronic Hepatitis B Patients Receiving 7 Years of Entecavir Therapy","volume":"129","author":"Zhang","year":"2016","journal-title":"Chin Med J"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.24326","article-title":"Serum Hepatitis B Surface Antigen Correlates With Tissue Covalently Closed Circular DNA in Patients With Hepatitis B-Associated Hepatocellular Carcinoma","volume":"88","author":"Wang","year":"2016","journal-title":"J Med Virol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1767","article-title":"Analysis of HBsAg Immunocomplexes and cccDNA Activity During and Persisting After NAP-Based Therapy","volume":"5","author":"Bazinet","year":"2021","journal-title":"Hepatol Commun"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200737552","article-title":"Functional Dichotomy of Plasmacytoid Dendritic Cells: Antigen-Specific Activation of T Cells Versus Production of Type I Interferon","volume":"38","author":"Jaehn","year":"2008","journal-title":"Eur J Immun"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2007","article-title":"Immune Function of Plasmacytoid Dendritic Cells, Natural Killer Cells, and Their Crosstalk in HBV Infection","volume":"28","author":"Golsaz-Shirazi","year":"2018","journal-title":"Rev Med Virol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1139","article-title":"Plasmacytoid Dendritic Cell Biology and its Role in Immune-Mediated Diseases","volume":"9","author":"Ye","year":"2020","journal-title":"Clin Transl Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.891424\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T05:52:00Z","timestamp":1652939520000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.891424\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,19]]},"references-count":39,"alternative-id":["10.3389\/fimmu.2022.891424"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.891424","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,19]]},"article-number":"891424"}}